Inebilizumab cut MG exacerbations and rescue therapy use in MINT, and a post hoc analysis found similar responses regardless ...
Non-US-born adults had higher CRC screening nonadherence than US-born adults, particularly those with less than 15 years of US residence.
The UCSF Health–based leukemia and lymphoma specialist outlines chemo-free DLBCL, dual-targeted CAR T-cell therapy, and MRD-guided deescalation.
In the phase 3 ECLIPSE 1 trial, 44% on elebsiran plus tobevibart met the primary end point, with no treatment stops due to serious adverse events.
Crescent Moore, PharmD, PhD, explained how health plans can evaluate menopause therapies, audit coverage, and measure ...
The once weekly self-injected treatment is the first dual-binding nanobody C5 inhibitor approved for adults with AChR ...